中华医学会系列杂志
Chinese Journal of Clinicians ISSN 1674-0785 CN 11-9147/R 联系我们网站地图帮助中心
期刊导读
期刊存档

您的位置:首页>> 文章摘要

替格瑞洛在老年不稳定型心绞痛患者择期行经皮冠状动介入治疗中的疗效及安全性

王宇航 谷新顺 汪雁博 范卫泽 姜云发 李一 傅向华

050000 石家庄,河北医科大学第二医院心血管内科

谷新顺,Email: 13930139688@163.com

摘 要:目的 观察替格瑞洛在老年不稳定型心绞痛(UA)患者择期行经皮冠状动脉介入(PCI)治疗中的疗效及安全性。方法 连续入选2014年1月至2015年12月于河北医科大学第二医院心内科初次就诊且年龄≥65岁的UA患者。根据随机数字表将入选患者分成氯吡格雷组(63例)和替格瑞洛组(65例)。替格瑞洛组患者入院后接受替格瑞洛180 mg负荷量,继之以90 mg每日两次维持;氯吡格雷组患者给予氯吡格雷组300 mg负荷剂量,以75 mg每日一次口服维持。记录所有患者入院、PCI术前的血小板聚集率(PAR),观察血小板高反应性(HPR)发生情况。所有患者均择期完成PCI手术,比较两组患者PCI术后TIMI血流和TIMI心肌灌注分级(TMPG)的变化。比较两组患者住院期间及出院后1个月内的主要心脏不良事件(MACE)及出血事件的发生情况。结果 两组间患者基线资料如年龄、性别、吸烟史、高血压、糖尿病、血脂异常、缺血性卒中、GRACE评分、CRUSADE评分、BNP和肌酐水平等差异均无统计学意义(P>0.05)。两组患者介入途径、支架置入相关血管、术后心肌灌注水平和造影用量等差异均无统计学意义(P>0.05)。两组患者基线血小板参数(血小板计数、血小板分布宽度、平均血小板体积、PAR)差异均无统计学意义(P>0.05)。PCI术后1个月随访发现,两组患者PAR均较基线水平明显降低(均P<0.01),替格瑞洛组PAR下降更为明显(P<0.01),且替格瑞洛组HPR发生率明显低于氯吡格雷组(27.0% vs. 3.1%,P<0.001)。替格瑞洛组MACE发生率明显低于氯吡格雷组(14.3% vs. 1.5%,P=0.008)。两组患者出血并发症发生率差异无统计学意义(P>0.05),但是替格瑞洛组呼吸困难的发生率明显高于氯吡格雷组(0 vs. 9.2%,P=0.028)。结论 替格瑞洛在老年UA患者择期行PCI治疗中是安全有效的。

关键词: 心绞痛,不稳定型; 血管成形术,经腔,经皮冠状动脉; 老年人; 替格瑞洛

Efficacy and safety of ticagrelor in the elderly patients with unstable angina undergoing elective percutenous coronary intervention

Wang Yuhang, Gu Xinshun, Wang Yanbo, Fan Weize, Jiang Yunfa, Li Yi, Fu Xianghua.

Department of Vasculocardiology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China

Gu Xinshun, Email: 13930139688@163.com

Abstract:Objective To evaluate the efficacy and safety of ticagrelor in the elderly patients with unstable angina (UA) undergoing elective percutenous coronary intervention (PCI). Methods From January 2014 to December 2015, patients with UA and age≥65 year-old who were admitted to the Second Hospital of Hebei Medical University were enrolled in this study. All the patients were randomized into clopidogrel group (63 cases) and ticagrelor group (65 cases). Patients in clopidogrel group were received 300 mg clopidogrel followed by 75 mg per day. Patients in ticagrelor group were given 180 mg ticagrelor followed by 90 mg twice a day. The pre-PCI platelet aggregation rate and the creatinine of admission pre-PCI and post-PCI were recorded. All the patients underwent elective PCI. TIMI flow, and TIMI myocardial perfusion grade (TMPG) were compared. The major adverse cardiac events (MACE) and bleeding events were followed up for 1 month. Results The baseline clinical characteristics were similar between the two groups, including age, gender distribution, histories, GRACE score and CRUSADE score (P>0.05). No differences in interventional protocols were found (P>0.05). There were no differences in the baseline levels of platelet counts, platelet distribution width, mean platelet volume and platelet aggregation rate (PAR) (P>0.05). After 1-month follow-up, the levels of PAR were decreased in both groups (P<0.01), and it was much more lower in the ticagrelor group (27.0% vs. 3.1%, P<0.001). The incidence of MACE was also lower in the ticagrelor group during the follow-up (14.3% vs. 1.5%, P=0.008). The incidence of bleeding complications were not significantly different, but the incidence of dyspnea in the ticagrelor group was more than that in the clopidogrel group (0 vs. 9.2%, P=0.028). Conclusion It is effective and safe of ticagrelor in the elder patients with UA undergoing elective PCI.

Key words:Angina, unstable; Angioplasty, transluminal, percutaneous coronary; Aged; Ticagrelor

评论   收藏 全文阅读: FullText |

文献标引:王宇航 谷新顺 汪雁博 范卫泽 姜云发 李一 傅向华.替格瑞洛在老年不稳定型心绞痛患者择期行经皮冠状动介入治疗中的疗效及安全性[J/CD].中华临床医师杂志:电子版,2017,11(4):560.

参考文献:
  [1] 杨燕飞. 慢性压力对冠心病发生、进展及预后的影响[J]. 心血管病学进展, 2013, 34(2): 238-240.

  [2] Rognoni A, Cavallino C, Lupi A, et al. Ticagrelor: a novel drug for an old problem[J]. Recent Pat Cardiovasc Drug Discov, 2014, 9(1): 51-57.

  [3] Criniti JM, Izcovich A, Popoff F, et al. Ticagrelor in acute coronary syndrome. Explaining the inexplicable[J]. Medicina (B Aires), 2014, 74(3): 239-244.

  [4] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009, 361(11): 1045-1057.

  [5] Yıldırır. What is new in 2015 ESC nonST Elevation Acute Coronary Syndrome Guideline?[J]. Turk Kardiyol Dern Ars, 2016, 44(1): 15-19.

  [6] 殷华勇. 老年冠心病患者的特点和危险因素临床研究[J]. 心血管康复医学杂志, 2014, 23(3): 256-258.

  [7] 陈伟伟, 高润霖, 刘力生, 等. 《中国心血管病报告2014》概要[J]. 中国循环杂志, 2015, 30(7): 617-622.

  [8] Anderson JL, Antman EM, Harold JG, et al. Clinical practice guidelines on perioperative cardiovascular evaluation: collaborative efforts among the ACC, AHA, and ESC[J]. Circulation, 2014, 130(24): 2213-2214.

  [9] 沈节艳, 何奔, 刘建平, 等. 75岁以上老年冠心病患者的介入治疗及疗效观察[J]. 中国介入心脏病学杂志, 2005, 13(6): 367-370.

  [10] Balla S, Nusair MB, Alpert MA. Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management[J]. Curr Opin Pharmacol, 2013, 13(2): 192-199.

  [11] Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study[J]. J Am Coll Cardiol, 2010, 56(3): 185-193.

  [12] Bliden KP, Tantry US, Storey RF, et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies[J]. Am Heart J, 2011, 162(1): 160-165.

  [13] 杨影红, 孙鑫, 田野. 替格瑞洛增强腺苷生物学效应的研究进展[J]. 临床心血管病杂志, 2015, 31(2): 122-124.

  [14] Storey RF, James SK, Siegbahn A, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study[J]. Platelets, 2014, 25(7): 517-525.

  [15] Li H, Butler K, Yang L, et al. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study[J]. Clin Drug Investig, 2012, 32(2): 87-97.

  [16] Xue HJ, Shi J, Liu B, et al. Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS[J]. Platelets, 2016, 27(5): 440-445.

  [17] Nylander S, Femia EA, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism [J]. J Thromb Haemost, 2013, 11(10): 1867-1876.

临床论著

中国汉族人群抑郁障碍严重程度与儿童期虐待、人格特征和应激性生活事件的相关关系

张豪 李素萍 杜巧荣 李忻蓉 孙宁 张克让. .中华临床医师杂志:电子版 2017;11(4):535.

摘要 FullText 评论 收藏

降钙素原清除率用于评估脓毒性休克患者预后的观察研究

周柱江 刘长智 刘海峰 叶志钢 卢剑海 左六二. .中华临床医师杂志:电子版 2017;11(4):539.

摘要 FullText 评论 收藏

原发灶及转移灶放疗在Ⅳ期寡转移非小细胞肺癌中的疗效分析

张矛 孙涛 崔洪霞 张劲. .中华临床医师杂志:电子版 2017;11(4):543.

摘要 FullText 评论 收藏

能谱CT对炎性病变与肺癌的鉴别诊断价值

唐春耕1 尹喜2 王成伟2. .中华临床医师杂志:电子版 2017;11(4):550.

摘要 FullText 评论 收藏

双低剂量联合低流速注射在双源CT冠状动脉血管成像中的应用

汤振华. .中华临床医师杂志:电子版 2017;11(4):555.

摘要 FullText 评论 收藏

替格瑞洛在老年不稳定型心绞痛患者择期行经皮冠状动介入治疗中的疗效及安全性

王宇航 谷新顺 汪雁博 范卫泽 姜云发 李一 傅向华. .中华临床医师杂志:电子版 2017;11(4):560.

摘要 FullText 评论 收藏

原发性高血压患者血清总胆红素水平与左心室肥厚的相关性研究

梁金花1 冯颖妍1 冯志仪1 周祖勇2 周红辉3. .中华临床医师杂志:电子版 2017;11(4):566.

摘要 FullText 评论 收藏

抗氨甲酰化蛋白抗体对类风湿关节炎的诊断价值

郑晓 王玉梅 刘秀梅 . .中华临床医师杂志:电子版 2017;11(4):570.

摘要 FullText 评论 收藏

骨折延迟愈合相关miRNAs检测

陈磊 刘黎军 张胜利 杨金星 黄俊锋 尤微 韩云. .中华临床医师杂志:电子版 2017;11(4):574.

摘要 FullText 评论 收藏

甲状腺结节973例超声与病理特点

宋立稳 柳林 卢洪文 刘长山. .中华临床医师杂志:电子版 2017;11(4):578.

摘要 FullText 评论 收藏

水通道蛋白3表达及催乳素浓度与羊水量异常相关性

徐静 许红雁 范舒舒 黄伟. .中华临床医师杂志:电子版 2017;11(4):583.

摘要 FullText 评论 收藏

胃食管反流病的特点及与牙周疾病相关性研究

古孜努尔·阿巴斯1,2 米尔阿迪力·阿布都卡迪尔2 木合塔尔·霍加2. .中华临床医师杂志:电子版 2017;11(4):588.

摘要 FullText 评论 收藏